FSA
Fort Sheridan Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $50.1K | Hold |
55,177
| – | – | 0.01% | 251 |
|
|
2025
Q1 | $24.9K | Hold |
55,177
| – | – | ﹤0.01% | 247 |
|
|
2024
Q4 | $27.7K | Buy |
55,177
+23,000
| +71% | +$11.6K | ﹤0.01% | 244 |
|
|
2024
Q3 | $29.1K | Hold |
32,177
| – | – | ﹤0.01% | 247 |
|
|
2024
Q2 | $32.1K | Hold |
32,177
| – | – | 0.01% | 233 |
|
|
2024
Q1 | $47.6K | Sell |
32,177
-8,754
| -21% | -$13K | 0.01% | 204 |
|
|
2023
Q4 | $44.6K | Sell |
40,931
-43,000
| -51% | -$46.9K | 0.01% | 199 |
|
|
2023
Q3 | $99K | Hold |
83,931
| – | – | 0.02% | 190 |
|
|
2023
Q2 | $118K | Buy |
83,931
+10,000
| +14% | +$14.1K | 0.03% | 197 |
|
|
2023
Q1 | $111K | Sell |
73,931
-10,000
| -12% | -$15K | 0.03% | 189 |
|
|
2022
Q4 | $98.2K | Hold |
83,931
| – | – | 0.03% | 179 |
|
|
2022
Q3 | $95K | Buy |
83,931
+5,000
| +6% | +$5.66K | 0.03% | 178 |
|
|
2022
Q2 | $125K | Buy |
78,931
+3,000
| +4% | +$4.75K | 0.04% | 173 |
|
|
2022
Q1 | $117K | Buy |
75,931
+23,000
| +43% | +$35.4K | 0.03% | 179 |
|
|
2021
Q4 | $130K | Buy |
52,931
+5,000
| +10% | +$12.3K | 0.04% | 186 |
|
|
2021
Q3 | $121K | Hold |
47,931
| – | – | 0.04% | 183 |
|
|
2021
Q2 | $137K | Buy |
47,931
+3,000
| +7% | +$8.58K | 0.05% | 174 |
|
|
2021
Q1 | $106K | Buy |
+44,931
| New | +$106K | 0.04% | 158 |
|